Holen Sie sich die Stockscreener-App
10.14
2.11%
0.21
Handel nachbörslich:
10.14
Schlusskurs vom Vortag:
$9.93
Offen:
$9.99
24-Stunden-Volumen:
2.23M
Relative Volume:
1.05
Marktkapitalisierung:
$744.45M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-2.1713
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+10.10%
1M Leistung:
+19.01%
6M Leistung:
+5.41%
1J Leistung:
-61.63%
1-Tages-Spanne:
$9.80
$10.14
1-Wochen-Bereich:
$9.25
$10.18
52-Wochen-Spanne:
$5.90
$28.83
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.14 | 729.04M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Historical volatility pattern of Arvinas Inc. visualized2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com
How to escape a deep drawdown in Arvinas Inc.July 2025 News Drivers & Fast Entry Momentum Alerts - newser.com
Is Arvinas Inc. still worth holding after the dip2025 Retail Activity & Real-Time Volume Triggers - newser.com
Live market analysis of Arvinas Inc.Weekly Trend Recap & Technical Confirmation Alerts - newser.com
Can Arvinas Inc. stock beat analyst upgradesJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Has Arvinas Inc. formed a bullish divergenceEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Order flow analysis tools used on Arvinas Inc.July 2025 Summary & Long-Term Growth Portfolio Plans - newser.com
Can technical indicators confirm Arvinas Inc.’s reversalJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Is Arvinas Inc. stock a top pick in earnings seasonPrice Action & Weekly High Return Forecasts - newser.com
BTIG Maintains Buy Rating on Arvinas (ARVN), Raises Price Target to $14.00 | ARVN Stock News - GuruFocus
BTIG Maintains Arvinas (ARVN) Buy Recommendation - Nasdaq
Arvinas stock price target raised to $14 from $10 at BTIG on KRASG12D degrader potential - Investing.com
Arvinas Inc. stock chart pattern explainedEarnings Risk Report & Expert Approved Trade Ideas - newser.com
Published on: 2025-10-30 00:10:42 - newser.com
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Arvinas (NASDAQ: ARVN) sets Nov. 5 webcast to review Q3 2025 results - Stock Titan
Why Arvinas Inc. stock appeals to analystsJuly 2025 Breakouts & AI Driven Price Forecasts - fcp.pa.gov.br
Why Arvinas Inc. stock is a must watch in 2025Market Activity Summary & Precise Trade Entry Recommendations - Fundação Cultural do Pará
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Can Arvinas Inc. stock hit analyst price targetsEarnings Summary Report & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):